Media headlines about vTv Therapeutics (NASDAQ:VTVT) have been trending somewhat positive this week, according to Accern. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. vTv Therapeutics earned a news impact score of 0.13 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 47.4543493526532 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Several analysts have commented on VTVT shares. Roth Capital started coverage on shares of vTv Therapeutics in a research note on Thursday, March 8th. They set a “buy” rating and a $17.00 price objective for the company. Canaccord Genuity set a $15.00 price objective on shares of vTv Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 21st. Northland Securities started coverage on shares of vTv Therapeutics in a research note on Thursday, February 8th. They set an “outperform” rating and a $28.00 price objective for the company. Finally, Zacks Investment Research cut shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $16.50.
vTv Therapeutics (NASDAQ VTVT) traded down $0.23 on Wednesday, hitting $6.24. 89,721 shares of the company traded hands, compared to its average volume of 207,843. The company has a debt-to-equity ratio of -0.10, a quick ratio of 0.76 and a current ratio of 0.76. vTv Therapeutics has a 1 year low of $3.57 and a 1 year high of $8.40. The firm has a market cap of $224.76, a PE ratio of -3.71 and a beta of 1.48.
TRADEMARK VIOLATION NOTICE: This story was first posted by BBNS and is the property of of BBNS. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://baseballnewssource.com/2018/03/14/vtv-therapeutics-vtvt-given-media-sentiment-rating-of-0-13/2029262.html.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.